Phosphate and fibroblast growth factor 23 (FGF-23) in early chronic kidney disease – their importance in bone mineral metabolism and as cardiovascular risk factors.

磷酸盐和成纤维细胞生长因子 23 (FGF-23) 在早期慢性肾病中的作用 — 它们在骨矿物质代谢中的重要性以及心血管危险因素。

• 批准号: nhmrc : 1056378
• 负责人: Dr Sven-Jean Tan
• 金额: $ 9.4万
• 依托单位: Melbourne Vic.
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phosphate-fibroblast-growth-risk-factors/112549
• 关键词: Phosphate; fibroblast; growth; factor; 23

In the chronic kidney disease (CKD) population, serum phosphate and fibroblast growth factor-23 (FGF-23), a phosphate regulating hormone, are strongly associated with mortality and cardiovascular disease (CVD). This thesis will examine phosphate homeostasis in clinical studies necessary to address this problem, as phosphate and FGF-23 are potential therapeutic targets.

在慢性肾病（CKD）人群中，血清磷酸盐和成纤维细胞生长因子-23（FGF-23）（一种磷酸盐调节激素）与死亡率和心血管疾病（CVD）密切相关。本论文将在临床研究中研究磷酸盐稳态，以解决这一问题，因为磷酸盐和FGF-23是潜在的治疗靶点。